The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 61.04 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as Terns Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Hansoh Option And License Agreement$1.0M
Leadership changes
From Terns Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Robert Azelby · director · appointmenteff. 2025-02-20
- Carl Gordon · Directors · departureeff. 2025-02-20
- Heather Turner · director · appointmenteff. 2024-11-18
Latest filings
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-27
- 10-K · Annual report2026-03-30
- 8-K · Company announcement2026-03-25
- 8-K · Company announcement2026-01-22
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Terns Pharmaceuticals, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Terns Pharmaceuticals, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.